Funding from the European Community (Horizon program) has been approved for the biomedical research program called ARACHNID (Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD), which will be carried out in collaboration between BIOGENERA’s R&D team and the research group of Prof. Elisa Cimetta of the University of Padua.
The research program aims to develop a new, unique and automated bionanotechnology platform for simultaneous analysis of the complex evolution of human tumor-metastasis-on-a-chip (TMOC) in various human organ models.
In fact, the spread of cancer metastasis to various organs is what makes cancers deadly. The platform will aim to simulate the evolution of cancer metastasis in organs, avoiding the use of animals for experimentation.
The platform will also be used to evaluate the effect of BIOGENERA’s new anti-cancer drug BGA002, intended for the treatment of neuroblastoma and other pediatric and adult cancers with alterations in the MYCN tumor gene, which are frequently associated with aggressive and metastatic tumors.
The results of biotechnological and pharmacological research could be a major step forward, reducing costs and time for the development of increasingly innovative and targeted therapies, with the goal of eliminating the use of animals in experimentation. They will also enable prediction of the anti-metastatic efficacy of the new drug BGA002 and other new drugs.
